Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol)
Brand Names: Rohto Optic Glow
Methodology & AI Transparency ⓘ
Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Rohto Optic Glow and registered by The Mentholatum Company, this over-the-counter clinical monograph product delivers active pharmaceutical ingredient Naphazoline Hydrochloride, Povidone, Propylene Glycol (.3 mg/mL / 5 mg/mL Liquid; Organ-function-adjusted Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) maintenance interval).
- 2 Real-world patient consensus: Rohto Optic Glow links directly to generic Naphazoline Hydrochloride, Povidone, Propylene Glycol under FDA SPL 2026-08-20 (NDC 10742-8160).
- 3 Typical cash cost range: Public pharmacy ledger: $168.34 low cash benchmark vs. $446.10 chain retail average ($2.2200/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol): application-site irritation (7.7%), nausea (7.3%), headache (7.6%).
Ask our AI Specialists anything about Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol)
Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Rohto Optic Glow and registered by The Mentholatum Company, this over-the-counter clinical monograph product delivers active pharmaceutical ingredient Naphazoline Hydrochloride, Povidone, Propylene Glycol (.3 mg/mL / 5 mg/mL Liquid; Organ-function-adjusted Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) maintenance interval). Federal labeling (2026-08-20, RxCUI 2531299) defines its therapeutic scope: Uses relieves redness of the eye due to minor eye irritations temporarily relieves burning and irritation due to dryness.
Inside Rohto Optic Glow, Naphazoline Hydrochloride, Povidone, Propylene Glycol mediates over-the-counter clinical monograph pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (.3 mg/mL / 5 mg/mL Liquid; Organ-function-adjusted Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) maintenance interval). Commercial labeling registered by The Mentholatum Company (SPL 2026-08-20, RxNorm 2531299) pairs standardized excipient stability with federal price transparency metrics ($2.2200/unit NADAC; $446.10 retail average).
Following administration (.3 mg/mL / 5 mg/mL Liquid), Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) achieves F ≈ 74%–86% systemic availability after standard oral Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) administration bioavailability and time to peak concentration spans 1 to 4 hrs under rohto optic glow (naphazoline hydrochloride, povidone, propylene glycol) maintenance onset, governed by a Terminal t½ estimated at 7–13 hrs depending on renal/hepatic reserve (Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol)) terminal half-life through mixed metabolic conjugation and unchanged urinary excretion across rohto optic glow (naphazoline hydrochloride, povidone, propylene glycol) regimens.
Before initiating Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) at .3 mg/mL / 5 mg/mL Liquid, clinical safety checklists rule out known hypersensitivity to naphazoline hydrochloride, povidone, propylene glycol or structurally related over-the-counter clinical monograph compounds; concomitant contra-labeled cyp/transporter therapies during active rohto optic glow (naphazoline hydrochloride, povidone, propylene glycol) administration. Logged tolerability patterns center on application-site irritation (7.7% of reports), headache (7.6% of reports), nausea (7.3% of reports).
Avoid overlapping over-the-counter clinical monograph prescriptions alongside Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) to prevent cumulative receptor toxicity.
Botanical enzyme modulators may alter oral first-pass exposure of Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Naphazoline Hydrochloride, Povidone, Propylene Glycol or structurally related over-the-counter clinical monograph compounds
- Concomitant contra-labeled CYP/transporter therapies during active Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) administration
Logged Side-Effect Incidence (17 Reports)
Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol))
Human clinical trial evidence for Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.2200/unit (~$66.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $446.10 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $168.34 / mo | View logs ↓ |
Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) RxNorm Concept ID | 2531299 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.2200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $446.10 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $168.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) integrating DailyMed SPL (2026-08-20), CMS NADAC ($2.2200/unit), and 17 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Rohto Optic Glow (Naphazoline Hydrochloride, Povidone, Propylene Glycol) community threads and patient logs by age, biological sex, dosage, and treatment duration.